MedTrace Logo

Scenario Tailored Opioid Messaging Program (STOMP) to Improve Risk Understanding in Young Adults

NCT03863353 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 503

Last updated 2022-04-06

Study results available
· View outcomes & findings →

Summary

Legitimate prescription opioid use during adolescence has been associated with later prescription opioid misuse and substance use disorder symptoms during adulthood. Thus, primary prevention interventions for older adolescents and young adults (15-24 yrs) at the time of prescribing are imperative.

The goal of our research is to improve opioid analgesic safety and efficacy by optimizing opioid risk recognition and informed decision-making among 15-24 year olds who are prescribed these agents for home use. Young adults and older adolescents who manage their own prescription pain medicines need to recognize opioid-related risks and make decisions that will both reduce these risks yet ensure effective pain relief. The proposed research will evaluate new strategies to help subjects learn about opioid risks and make safe and effective analgesic decisions. 355 subjects who are undergoing an elective surgical procedure will be recruited. Subjects will be randomized to receive the new educational routine information. Subjects' knowledge and perceptions will be evaluated at baseline and at critical times after surgery.

Conditions

  • Pain, Postoperative
  • Medication Adherence
  • Opioid Use
  • Knowledge, Attitudes, Practice
  • Risk Reduction Behavior

Interventions

BEHAVIORAL

Educational Intervention

This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.

Sponsors & Collaborators

Principal Investigators

  • Terri Voepel-Lewis, PhD · University of Michigan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
15 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2021-12-01
Completion
2021-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03863353 on ClinicalTrials.gov